Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study
Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC\&UES) explores radical radio(chemo)therapy efficacy and safety
• Age 18 and older.
• Confirmation of esophageal cancer through histopathology or cytology.
• Primary tumor location within the cervical or upper thoracic segment, extending from the upper esophageal sphincter to the azygos vein.
• Absence of distant metastasis.
• Patients unable or unwilling to undergo surgical treatment for various reasons.
• Receipt of radical radiotherapy as the first-line treatment, with or without chemotherapy, immunotherapy, or targeted therapy.
• Undergoing conventional radiation therapy (1.8-2.0Gy per session, once per day).
• Receiving 3DCRT or IMRT radiotherapy.
• Availability of complete radiotherapy prescription dose information and follow-up records.